Aptahems latest patent application is published

Aptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe applications with the priority date 3 October 2017. The patent application refers to Apta-1 and has the title ”A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties” which will give Aptahem the possibility to apply for patent protection in up to 150 countries within approximately one year’s time. The company currently evaluates the most value increasing geographies from a strategic perspective where patent protection is desirable.

The patent application was submitted after acheiving new, positive results in a number of preclinical studies. The scope of the protection is designed to cover the therapeutical protection for the company’s lead candidate Apta-1 and the improvement of the molecular Apta-1 structure. Thus, the protection covers the therapeutical effect of Apta-1 as anti-coagulant, anti-inflammatory and organ protective in addition to its underlying mechanisms of action. These effects are important in a range of disease areas and the patent application is meant to give Aptahem exclusive rights to use Apta-1 in, for instance, disease conditions related to myocardial infarction, thrombosis/embolisms, stroke, preeclampsia, diabetes, sepsis, rheumatoid arthritis, psoriasis, lupus, atopical dermatitis, cancer, infections, poisoning, organ failure and a range of other complications.

Aptahem’s CEO, Mikael Lindstam, comments: ”We are very pleased to see that this application finally has been made public. The application was submitted on the 3 October 2017 and it describes our scientific results up to the date of application. The publishing of the document will make our communication with external parties much easier and facilitates the transfer of information in continued collaboration and licensing discussions.”

The PCT application, with number WO/2019/068766, and the document can be read in full via updated, publicly available data basis.

* Patent Cooperation Treaty, PCT, is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent Offices in what is called the “national phase”.
Source: World Intellectual Property Organization (WIPO, www.wipo.int)

For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Email: ml@aptahem.com

About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.